Hot and Ready
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$4.87 as I sit here after 7+ years. Based on his flubs and Excellence trial results he needs his butt in a vise for his lack of leadership.
We need a CEO that makes things happen. WTF is Ma doing. Screw 3rd party review. Obvious by now it isn't coming. Either publish Alz data and fold the tent or deal with the success. His "way" leads to much pain. Dumkoff.
Amen get rid of this guy.
Release the damm Alz data ya effing fool.
That would be very cool
So Fritzy has not shared the ALZ data. It makes one pause after Kun has been around for 15 months. Rett Avatar was switched to AUC, Excellence missing endpoints, and Stat Sig PDD dying slowly. Come after me if you want BUT TRUTH is he not the guy!
Why should anyone respect this underqualified accountant? The Board needs to protect the shareholder or they will need a cushion for the witness chair!
George gets aroused whenever Missling announces anything. If Missling was an 80-1 shot in a horse race George who sell you on betting on him.
"Very nicely" put
Will we have NDA by 4Q 2026?
more potent.
So is the problem the data? or the lack of confidence of what the CEO says? or both? Enquiring minds need to know.
Agreed but it's the Ides of March. Kun was hired Jan 2023.
Well 4 months have gone by. Who will the FDA tell Missling? Sure we'll we'll never know because he will sit on it. Claw back his options. We've gone from $31. to $5.
Enquiring minds want to know.....Are we filing and NDA for Rett or calling it a fail? Or just not give clear communications again?
Until we get a seasoned professional at CEO, we will suffer the consequences from his poor communication skills and lack of a sense of urgency.
With his pals running IR and Accounting he continues without a professional PR firm. Relying on his skill set is just micro managing.
WGT need to give serious doubt to the validity of what comes out of his mouth.
Litigation will come before approvals and there goes the 100M shelf.
Word salads cause law suits.
Is that why Missling hasn't acknowledged Rett Excellence as a FAIL.
AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
it a law firm in San Diego
Chris, I am still long. I have mentioned several times, including a missive to Chairman Ma, that Missling is a lawsuit waiting to happen. I doubt the big tutes will join in litigation.
I guess it's a means to press Missling to lead better, but I don't think he knows anything about leading.
More lawsuits will follow unless he drops his drawers on Rett and FDA.
Penny wise and pound foolish. Why do a trial if it's not worth anything. We need points on the board. if this stuff is good sell some equity and get a 371 Schizophrenia trial going. $14B is off the table.
We need a strategic plan with outside experts sitting in.
This happens when Bozo runes the Circus
Some say the trial wasn't big enough. Some say ...................... Missling wants Voucher is why
https://cslide.ctimeetingtech.com/adpd24/attendee/confcal/presentation/list?q=timo+grimmer
Results
The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48
weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226)
for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early AD.
In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P
= 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while
MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing
treatment to placebo.
anavex_mri.jpg
Conclusions
Among participants with early symptomatic AD, blarcamesine was generally safe, well tolerated and
significantly slowed clinical progression at 48 weeks, which is also corroborated by biomarkers from the
A/T/N spectrum, including plasma Aß42/40 ratio increase and reduction of brain atrophy in several key
regions of the brain measured by MRI.
ClinicalTrials.gov Identifier: NCT03790709.
Hide
https://cslide.ctimeetingtech.com/adpd24/attendee/confcal/presentation/list?q=timo+grimmer
Results
The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48
weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226)
for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early AD.
In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P
= 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while
MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing
treatment to placebo.
anavex_mri.jpg
Conclusions
Among participants with early symptomatic AD, blarcamesine was generally safe, well tolerated and
significantly slowed clinical progression at 48 weeks, which is also corroborated by biomarkers from the
A/T/N spectrum, including plasma Aß42/40 ratio increase and reduction of brain atrophy in several key
regions of the brain measured by MRI.
ClinicalTrials.gov Identifier: NCT03790709.
Hide
FDA snitches won't go away at ANY time.
So keep trusting Missling I guess.
I have a Question for the more knowledgeable folks on the Board. Missling has said many times that he was taking direction from the FDA in supposed meetings. We also know he wants to sneak this past BP "his way" I'm not looking for supposition but people in the know.
Is it possible they have already submitted the NDA for ALz to the FDA without any fanfare?
What do you think Missling would allow Grimmer to say?
T I am not alone in that belief, however, since you have stated that I'll go with your interpretation.
Should it be approved it could be months before Missling choosing a licensee. Maybe it could be a long wait as long as the 3rd party review.
January 16th?
Missling stated he would not do a license prior to approval to get the shareholders the best deal. Impossible! Distribution and Sales are part of submission, That is Why I believe we have no submission, not the 3rd party review.
Remember, it has to be done, Missling's way! LOL
You are Right. Sorry, I get all these guys confused. What would I do without your relentless watchdog behavior?
Grimmer is the guy Mayo interviewed that wasn't all happy about 273
No Lily is down today. I believe FDA has them on hold.
I think the street might be wary of Sabbagh dropping some Numbers to grease the skids in Europe especially with new Lilly news.
She must think you are a great lover. LOL
Missling's 15 minutes turned into 30!
EXACTLY
Why I'd the National Enquirer taking so long with the 3rd party review. Is George writing it? Of so it should be done by now.
If you can borrow or rent a Bemer device I highly recommend. It help get the garbage out of your blood and bring nutrition to the inflamed area. I uses it for a SI joint fusion from a Friday surgery on Saturday and was up and went to church on Sunday. Gets rid of inflammation which helps with pain. GOOD LUCK.
Knowing your going to listen to Grimmer Saturday, can you post your honest impression of his presentation.